Publication:
Cellular and Humoral Responses Follow-up for 8 Months after Vaccination with mRNA-Based Anti-SARS-CoV-2 Vaccines

Simple item page
dc.contributor.authorGil-Manso, Sergio
dc.contributor.authorCarbonell, Diego
dc.contributor.authorPérez-Fernández, Verónica Astrid
dc.contributor.authorLópez-Esteban, Rocío
dc.contributor.authorAlonso, Roberto
dc.contributor.authorMuñoz, Patricia
dc.contributor.authorOchando, Jordi
dc.contributor.authorSanchez-Arcilla, Ignacio
dc.contributor.authorBellón, José María
dc.contributor.authorCorrea-Rocha, Rafael
dc.contributor.authorPion, Marjorie
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderComunidad de Madrid (España)
dc.contributor.funderFundación Familia Alonso
dc.date.accessioned2023-05-05T09:25:37Z
dc.date.available2023-05-05T09:25:37Z
dc.date.issued2022-07-12
dc.description.abstractVaccination against SARS-CoV-2 has become the main method of reducing mortality and severity of COVID-19. This work aims to study the evolution of the cellular and humoral responses conferred by two mRNA vaccines after two doses against SARS-CoV-2. On days 30 and 240 after the second dose of both vaccines, the anti-S antibodies in plasma were evaluated from 82 volunteers vaccinated with BNT162b2 and 68 vaccinated with mRNA-1273. Peripheral blood was stimulated with peptides encompassing the entire SARS-CoV-2 Spike sequence. IgG Anti-S antibodies (humoral) were quantified on plasma, and inflammatory cytokines (cellular) were measured after stimulation. We observed a higher response (both humoral and cellular) with the mRNA-1273 vaccine. Stratifying by age and gender, differences between vaccines were observed, especially in women under 48 and men over 48 years old. Therefore, this work could help to set up a vaccination strategy that could be applied to confer maximum immunity.es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipThis work was partially supported by grants from the Instituto de Salud Carlos III (ISCIII) (PI18/00506; COV20/00063), co-funded by ERDF (FEDER) Funds from the European Commission, “A way of making Europe”. This work was partially financed by the Madrid Community grant B2017/BMD3727 and the IiSGM Intramural grant PI-MP-2018. This work was partially funded by a grant from “Fundación Familia Alonso” (FFA-FIBHGM-2019). S.G-M. was supported by the Youth Employment Program, co-financed by the Madrid community and FEDER Founds (PEJ-2020-AI/BMD-17954), and by the ACT4COVID consortium (CellNex funding). The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation.es_ES
dc.format.number7es_ES
dc.format.page1676es_ES
dc.format.volume10es_ES
dc.identifier.citationBiomedicines. 2022 Jul 12;10(7):1676.es_ES
dc.identifier.doi10.3390/biomedicines10071676es_ES
dc.identifier.issn2227-9059es_ES
dc.identifier.journalBiomedicineses_ES
dc.identifier.pubmedID35884980es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/15982
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/Subprograma Estatal de Generación de Conocimiento/PI18 - Proyectos de investigacion en salud (AES 2018). Modalidad proyectos en salud. (2018)/PI18/00506es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/COV20/00063es_ES
dc.relation.publisherversionhttps://doi.org/10.3390/biomedicines10071676es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCOVID-19es_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectCellular responseses_ES
dc.subjectHumoral responseses_ES
dc.subjectmRNA-vaccineses_ES
dc.titleCellular and Humoral Responses Follow-up for 8 Months after Vaccination with mRNA-Based Anti-SARS-CoV-2 Vaccineses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationf4411902-c52c-4e77-afff-0f9d9e8d9e9f
relation.isAuthorOfPublication.latestForDiscoveryf4411902-c52c-4e77-afff-0f9d9e8d9e9f
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublicationc87c70a3-e023-4b6b-ac25-1b2d1b483786
relation.isFunderOfPublicationc22f0022-15f8-4b94-96e9-b5bb3da55a2a
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublication30293a55-0e53-431f-ae8c-14ab01127be9
relation.isPublisherOfPublication.latestForDiscovery30293a55-0e53-431f-ae8c-14ab01127be9

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
CellularHumoralResponsesFollow-up_2022.pdf
Size:
2.14 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Centro Nacional de Microbiología (CNM)
IiSGM - Instituto de Investigación Sanitaria Gregorio Marañón (Madrid)